Pretomanid

Our Pipeline

Pretomanid

PA-824

Nitroimidazole

Background:

Pretomanid is a nitroimidazole, a class of novel anti-bacterial agents. Pretomanid has been developed by TB Alliance and is approved by the US FDA to treat XDR-TB or treatment-intolerant/non-responsive MDR-TB, in combination with bedaquiline and linezolid, as part of the BPaL regimen. Early in pretomanid’s development, it was known as “PA-824.”

More information on pretomanid and BPaL can be found here.

Peer-reviewed publications

 

Clinical Trials

 

FDA Briefing Materials

Stage of Development:

Approved

Regimen Associations

This compound has appeared in the following regimens

Trial Associations

This compound has appeared in the following trials:

Trial Associations

This compound has appeared in the following trials